772 results on '"Decristoforo, Clemens"'
Search Results
2. Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
3. Advancing 6-bromo-7-[11C]methylpurine to clinical use: improved regioselective radiosynthesis, non-clinical toxicity data and human dosimetry estimates
4. Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework
5. The revision of the pharmaceutical legislation — it is time to act for nuclear medicine in Europe
6. Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
7. Proceedings of international symposium of trends in radiopharmaceuticals 2023 (ISTR-2023)
8. Improved quality control of [177Lu]Lu-PSMA I&T
9. The Regulatory Review of Radiotherapeutics: A European Perspective
10. Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
11. [111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial
12. Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
13. Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January-June 2020).
14. Automated production of [68Ga]Ga-DOTA-exendin-4 via fractionated radionuclide generator elution on a cassette based synthesis module
15. EANM guideline on quality risk management for radiopharmaceuticals
16. EANM position on the in-house preparation of radiopharmaceuticals
17. Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals
18. Biomimetic Analogues of the Desferrioxamine E Siderophore for PET Imaging of Invasive Aspergillosis: Targeting Properties and Species Specificity.
19. Editorial Board
20. Theranostic radiopharmacy for the nuclear medicine and molecular imaging
21. Radiopharmaceutical legislation
22. In vitro studies with radiopharmaceuticals
23. Enhancing Clinical Diagnosis for Patients With Persistent Pulmonary Abnormalities After COVID-19 Infection: The Potential Benefit of 68Ga-FAPI PET/CT
24. Development and validation of the HPLC method for quality control of radiolabelled DOTA-TATE and DOTA-TOC preparations
25. 68Ga-labelled desferrioxamine-B for bacterial infection imaging
26. Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [68Ga]Ga-PSMA-11-PET/CT in the evaluation of prostate cancer patients
27. Advancing 6-bromo-7-[11C]methylpurine to clinical use: improved regioselective radiosynthesis, non-clinical toxicity data and human dosimetry estimates.
28. Recommendations for Conducting Clinical Trials with Radiopharmaceuticals
29. Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals
30. Comparison of 68Ga-labeled RGD mono- and multimers based on a clickable siderophore-based scaffold
31. Modifying the Siderophore Triacetylfusarinine C for Molecular Imaging of Fungal Infection
32. PET and SPECT
33. Synthesis, in vitro and in vivo evaluation of 18F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors
34. Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy
35. The Siderophore Ferricrocin Mediates Iron Acquisition in Aspergillus fumigatus
36. Management of NENs with SSTR2-antagonist: how close are we to a clinical solution? The first results of the TECANT study: Novel 99m-Tc-labelled somatostatin antagonists in the diagnostic algorithm of neuroendocrine neoplasms - a feasibility study
37. Molecular Design of 68Ga- and 89Zr-Labeled Anticalin Radioligands for PET-Imaging of PSMA-Positive Tumors
38. Live-cell imaging with Aspergillus fumigatus-specific fluorescent siderophore conjugates
39. EANM guideline on the validation of analytical methods for radiopharmaceuticals
40. The new Regulation on clinical trials in relation to radiopharmaceuticals: when and how will it be implemented?
41. Highlights of the 30th Annual Congress of the EANM, Vienna 2017: “Yes we can – make nuclear medicine great again”
42. Development of the 99mTc-Labelled SST2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study
43. Current status of theranostics in prostate cancer
44. Improved Quality Control of [177Lu]Lu-PSMA I&T
45. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with 111In-CP04 in medullary thyroid carcinoma patients
46. From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial
47. 18th European Symposium on Radiopharmacy and Radiopharmaceuticals: Salzburg, Austria. 7-10 April 2016
48. Radionuclides: medicinal products or rather starting materials?
49. US and EU radiopharmaceutical diagnostic and therapeutic nonclinical study requirements for clinical trials authorizations and marketing authorizations
50. Fungal siderophore metabolism with a focus on Aspergillus fumigatus: impact on biotic interactions and potential translational applications.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.